Five-year Data on Ropeginterferon Alfa-2b Illustrate Durable Response at Five Years in People with Polycythemia Vera

PharmaEssentia to Present Long-Term Data on Ropeginterferon alfa-2b in Polycythemia Vera at Virtual ASH Annual Meeting

PharmaEssentia Appoints Raymond Urbanski, M.D., Ph.D., as U.S. Head of Clinical Development and Medical Affairs

Real-World Study Shows Promising Efficacy, Safety of Ropeg in MPN

Time Magazine: PharmaEssentia – The Formula for Success

U.S. FDA Accepts PharmaEssentia’s Application for Ropeginterferon Alfa-2b to Treat Polycythemia Vera